文献速递血栓与止血

成人持续性免疫性血小板减少症二线治疗疗效:系统评价与网状Meta分析

Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
PubMed 文献 · Br J Haematol · 2019-08-18

结果显示艾曲泊帕和罗米司亭相对安慰剂在血小板反应上最佳,且优于利妥昔单抗及rhTPO+利妥昔单抗;罗米司亭在短期疗效与SAE间平衡最佳。

要点

  • 艾曲泊帕和罗米司亭在血小板反应上优于利妥昔单抗及rhTPO+利妥昔单抗。
  • 罗米司亭在血小板计数排名最高,艾曲泊帕次之。
  • 罗米司亭在短期疗效与SAE间平衡最佳,艾曲泊帕次之。

核心结论

  • 罗米司亭和艾曲泊帕可能带来高疗效与安全性。
  • 与TPO受体激动剂相比,利妥昔单抗可能因疗效较低且并发症较高而无益。
  • 仍需长期临床结局的RCT。

研究设计与样本

  • 系统评价与网状Meta分析,仅纳入成人持续性ITP二线药物的RCT。

主要发现

  • 血小板计数排名:罗米司亭最高,其次为艾曲泊帕、rhTPO+利妥昔单抗、利妥昔单抗。
  • 出血风险排名:利妥昔单抗最低,其次为艾曲泊帕和罗米司亭;SAE风险排名:rhTPO+利妥昔单抗最高,其次为利妥昔单抗、艾曲泊帕和罗米司亭。

关键数值与推荐

  • 聚类排名显示罗米司亭在短期疗效与SAE间平衡最佳,艾曲泊帕次之。

临床怎么用

  • 成人持续性ITP二线治疗中,罗米司亭和艾曲泊帕可能兼顾疗效与安全性。
  • 利妥昔单抗相比TPO受体激动剂可能疗效较低且并发症较高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Persistent immune thrombocytopenia (ITP) patients require second-line treatments, for which information on clinical outcomes are lacking. A systematic review and network meta-analysis (NMA) were conducted. Only randomised controlled trials (RCT) of second-line drugs in adult persistent ITP patients with platelet response, platelet count, any bleeding or serious adverse events (SAE) outcome were eligible. Twelve RCTs (n = 1313) were included in NMA. For platelet response outcome, eltrombopag and romiplostin were the best relative to placebo; the former had a non-significant advantage [risk ratio (RR) = 1·10 (95% confidence interval: 0·46, 2·67)]. Both treatments were superior to rituximab and recombinant human thrombopoietin (rhTPO)+rituximab, with corresponding RRs of 4·56 (1·89, 10·96) and 4·18 (1·21, 14·49) for eltrombopag; 4·13 (1·56, 10·94) and 3·79 (1·02, 14·09) for romiplostim. For platelet count, romiplostim ranked highest, followed by eltrombopag, rhTPO+rituximab, and rituximab. For bleeding, rituximab had lowest risk, followed by eltrombopag and romiplostim. For SAEs, rhTPO+rituximab had highest risk, followed by rituximab, eltrombopag and romiplostim. From clustered ranking, romiplostim had the best balance between short-term efficacy and SAEs, followed by eltrombopag. In conclusion, romiplostim and eltrombopag may yield high efficacy and safety. Rituximab may not be beneficial due to lower efficacy and higher complications compared with the thrombopoietin receptor agonists. RCTs with long-term clinical outcomes are required.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Puavilai T, Thadanipon K, Rattanasiri S, et al. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. Br J Haematol. 2019. PMID: 31423574. doi:10.1111/bjh.16161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。